PROTAC oncology market seen hitting $4.14 billion by 2030

The targeted protein degradation oncology market is projected to grow from $1.3 billion in 2025 to $4.14 billion by 2030, according to The Business Research Company. Rising cancer incidence, more biotech R&D and expanding use of precision medicine are driving demand for therapies that can eliminate disease-causing proteins rather than only block them.

Why it matters: - Targeted protein degradation oncology, or PROTAC, is drawing attention because it can eliminate cancer-driving proteins that are difficult to address with traditional drugs. - The approach could help close a gap in oncology treatment for so-called undruggable proteins. - Faster adoption could reshape drug pipelines and expand treatment options for resistant cancers.

What happened: - The Business Research Company projected the PROTAC oncology market will rise from $1.3 billion in 2025 to $1.63 billion in 2026. - The report said the market will reach $4.14 billion by 2030. - The company published the forecast in its “Targeted Protein Degradation Oncology (PROTAC) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035.” - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also offered a free sample report and the full market report.

The details: - The market’s 2025-to-2026 growth rate was projected at 26.0%. - The forecast period through 2030 carries a 26.2% compound annual growth rate. - The report tied near-term growth to rising cancer incidence, more research and clinical trials, higher biotech and pharma R&D investment, and wider use of precision medicine in oncology. - Longer-term growth is linked to next-generation protein degradation platforms, demand for treatments that can address previously undruggable cancer proteins, biomarker-guided personalized cancer therapies, more clinical validation and additional collaboration funding. - The report highlighted AI-driven target discovery, tumor-specific PROTAC molecules, molecular glue degraders, lysosome-targeting chimera systems and hybrid therapies combining PROTAC with autophagy mechanisms as key trends. - PROTAC works by using the body’s protein breakdown systems to selectively remove proteins that drive cancer growth. - The approach is designed to improve treatment effectiveness and overcome resistance to existing drugs.

Between the lines: - The forecast suggests investors and drugmakers are treating protein degradation as a practical next wave in oncology, not just a lab-stage concept. - North America led the market in 2025 because of strong healthcare infrastructure, heavy R&D spending and active pharmaceutical partnerships. - Asia-Pacific is expected to grow the fastest during the forecast period as cancer prevalence rises, access to care expands and biopharmaceutical innovation accelerates. - The World Health Organization projected in February 2024 that global cancer cases could top 35 million by 2050, up 77% from about 20 million in 2022, underscoring the size of the treatment gap.

What's next: - The report expects more oncology drug pipelines to adopt PROTAC and other protein degradation platforms. - Additional clinical validation, partnership activity and innovation funding could determine how quickly the market scales. - The market’s expansion will likely depend on whether PROTAC therapies can keep advancing against hard-to-treat cancer targets.

The bottom line: - PROTAC is moving from a niche research strategy toward a major oncology market, with demand rising as cancer burden grows and traditional drug approaches hit their limits.